Reviewer: James M. Metz, MD
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 22 de mayo del 2007
Presenter: Jiamin Li
Presenter's Affiliation: Wanjie Proton Therapy Center, Zibo, China
Type of Session: Scientific
Hepatocellur Carcinoma (HCC) is one of the most common cancers in China and the 4th leading cause of cancer death world wide. Most patients present with advanced stage and 80% are not eligible for surgery at the time of presentation. Conventional radiation therapy is difficult to adminster due to the sensitivity of the normal liver to radiation which reduces the ability to deliver doses high enough to kill the HCC. Radiation induced liver damage (RILD) and destruction of large amounts of normal liver are common with conventional radiation, which has limited its utilzation. Protons can significantly spare normal tissue radiation exposure and may be a viable treatment for these patients with HCC.
Materials and Methods
As the authors state, HCC is a huge problem world wide and many patients are not candidates for surgical resection. Proton therapy may offer an important option for these patients with localized disease. The data presented in this study are consistent with those presented from other centers, particularly in Japan, where proton therapy is offering encouraging results and is becoming a standard treatment option offerered at these centers. Future studies need to better establish the fractionation schedule and total dose most effective for treatment. Efforts should be made towards the earlier stage patients that are not resectable, but still have reasonable liver function.
Nov 13, 2012 - For patients with hepatitis B virus-related hepatocellular carcinoma (HCC) who undergo curative liver resection, treatment with nucleoside analogues correlates with a reduced risk of HCC recurrence or death, according to a study published online Nov. 12 in the Journal of the American Medical Association to coincide with presentation at the annual meeting of the American Association for the Study of Liver Diseases, held from Nov. 9 to 13 in Boston.
Sep 29, 2010
Aug 24, 2011